Bod Science (ASX:BOD) Other Current Receivables: A$0.37 Mil (As of Jun. 2025)


ASX:BOD Bod Science Ltd ASX:BOD
12 GF Score
Price A$0.02
GF Value A$0.04
! 3 Warning Signs
View Full Analysis

What is Bod Science Other Current Receivables?

Bod Science ASX:BOD 12 Other Current Receivables is A$0.37 Mil as of Jun. 2025. GuruFocus rates ASX:BOD with a GF Score™ of 12/100 and a GF Value™ of A$0.04. The stock has 3 warning signs investors should review.

Bod Science's Other Current Receivables for the quarter that ended in Jun. 2025 was A$0.37 Mil.

Bod Science's quarterly Other Current Receivables declined from Jun. 2024 (A$0.17 Mil) to Dec. 2024 (A$0.00 Mil) but then increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.37 Mil).

Bod Science's annual Other Current Receivables increased from Jun. 2023 (A$0.10 Mil) to Jun. 2024 (A$0.17 Mil) and increased from Jun. 2024 (A$0.17 Mil) to Jun. 2025 (A$0.37 Mil).

Bod Science Other Current Receivables Related Terms

Bod Science Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Bod Science's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bod Science Other Current Receivables Chart

Bod Science Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 0.03 0.23 0.10 0.17 0.37

Bod Science Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.00 0.17 0.00 0.37
ASX:BOD
12GF Score
Bod Science Ltd ASX:BOD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bod Science Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$0.37 Mil mean?
Bod Science (ASX:BOD) has a Other Current Receivables of A$0.37 Mil as of Jun. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bod Science and its competitors.
Is Bod Science's Other Current Receivables too high?
Bod Science's current Other Current Receivables is A$0.37 Mil. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's Other Current Receivables compare to ZTS?
Bod Science's Other Current Receivables of A$0.37 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bod Science and its competitors. Bod Science's current Other Current Receivables is A$0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current Other Current Receivables of A$0.37 Mil. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current Other Current Receivables is A$0.37 Mil. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current Other Current Receivables is A$0.37 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bod Science (ASX:BOD) Overvalued in 2026?

Based on GuruFocus' analysis, Bod Science stock appears to be undervalued. The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.

Key valuation signals for ASX:BOD:

  • Other Current Receivables: A$0.37 Mil
  • GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bod Science Business Description

Address C/- Rodgers Reidy, 210 Clarence Street, Level 12, Sydney, NSW, AUS, 2000
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score

Get the complete analysis for ASX:BOD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.02
Price
A$0.04
GF Value